AbbVie announced that it will be building a $320 M manufacturing facility in Singapore to produce oncology and immunology products from its current pipeline. This will be its first manufactuirng site in Asia. It has R&D sites in Tokyo and Shanghai. The new plant is expected to come fully on line in 2019 and will add 250 workers. An AbbVie spokesman said the new plant will help "ensure geographic balance and continuity of product supply as well as increased capacity" for its biologics and small molecule drugs. Clearly this makes sense --- and may even be a bit late -- given the big economic shift toward Asian markets that will continue for decades. See PharmaTimes.
Posted by Bruce Lehr Feb 7th 2014.